Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-01-22FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for fluphenazine hydrochloride from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-01-22FDA Approved: TRIFLUOPERAZINE HYDROCHLORIDE — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for trifluoperazine hydrochloride from Sandoz Inc., confirming regulatory approval of the generic pr…
-
FDA approval · 2025-01-22FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for fluphenazine hydrochloride submitted by PAI Holdings, LLC dba PAI Pharma.
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: ACP-104 in Acutely Psychotic Subjects With Schizophrenia [Phase 2]
Phase 2 trial update of ACP-104 in acutely psychotic subjects with schizophrenia; the study has completed.
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: Investigation of Objective Cognitive Effort in Neuropsychological Evaluation of Psychotic Disorders
A clinical trial sponsored by University Hospital, Montpellier is investigating objective cognitive effort during neuropsychological evaluat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-01-16FDA Approved: HALOPERIDOL LACTATE — Supplemental Application (Mylan Institutional LLC)
FDA granted a supplemental approval for HALOPERIDOL LACTATE to Mylan Institutional LLC, issuing a supplemental application for this generic …
-
FDA approval · 2025-01-15FDA Approved: TRIFLUOPERAZINE HYDROCHLORIDE — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for trifluoperazine hydrochloride from Sandoz Inc., approving a generic product. The action makes th…
-
FDA approval · 2025-01-15FDA Approved: TRIFLUOPERAZINE HYDROCHLORIDE — Supplemental Application (Sandoz Inc.)
FDA approves a supplemental application for trifluoperazine hydrochloride (Sandoz Inc.), granting approval of the generic product. Trifluope…
-
FDA approval · 2025-01-15FDA Approved: TRIFLUOPERAZINE HYDROCHLORIDE — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for trifluoperazine hydrochloride by Sandoz Inc., enabling its generic product approval.
-
FDA approval · 2025-01-14FDA Approved: TRIFLUOPERAZINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for trifluoperazine hydrochloride from Mylan Pharmaceuticals Inc., enabling a generic version to…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Lifestyle Intervention for Young Adults With Serious Mental Illness [NA]
Completed results posted for a lifestyle intervention trial in young adults with serious mental illness, including schizophrenia, schizoaffe…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Effects of Auditory Stimulation on Sleep and Memory in Schizophrenia [NA]
This clinical trial update notes an ongoing study on the effects of auditory stimulation on sleep and memory in individuals with schizophren…
-
FDA approval · 2025-01-13FDA Approved: HALOPERIDOL — Supplemental Application (Fresenius Kabi USA, LLC)
FDA approved a supplemental application for HALOPERIDOL LACTATE, a generic injectable form of haloperidol from Fresenius Kabi USA, LLC.
-
FDA approval · 2025-01-13FDA Approved: ARIPIPRAZOLE — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA supplemental approval for ARIPIPRAZOLE by Amneal Pharmaceuticals LLC under an ANDA (ANDA 203906). This document records the supplemental…
-
FDA approval · 2025-01-13FDA Approved: ARIPIPRAZOLE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for aripiprazole by VistaPharm, LLC (ANDA 212870). The authorization pertains to changes to the appr…
-
FDA approval · 2025-01-13FDA Approved: LURASIDONE HYDROCHLORIDE — Original Application (Torrent Pharmaceuticals Limited)
FDA approved Lurasidone hydrochloride from Torrent Pharmaceuticals Limited as an original generic drug application (ANDA 208055).
-
CLINICAL_TRIALS trial_result · 2025-01-09Clinical Trial Update: A Shared Decision Making Training for Inpatients With Schizophrenia [NA]
This completed clinical trial evaluated a shared decision-making training program for inpatients with schizophrenia (and schizoaffective dis…
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia. [NA]
An exploratory, double-arm, 8-week study assessed the feasibility and acceptability of abbreviated CT-156 treatment in adults with schizophr…
-
CLINICAL_TRIALS research · 2025-01-02Clinical Trial Update: Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode [NA]
This clinical trial update reports recruitment status for a study evaluating telehealth aerobic exercise plus cognitive training to improve …
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug Monitoring
This clinical trial update examines the kinetics of clozapine and its metabolite norclozapine, associated side effects, and the optimal bloo…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated safety, tolerability, and pharmacokinetics of switching from oral risperidone to a risperidone implant …
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia [Phase 4]
A Phase 4 trial evaluated the effects of long-acting aripiprazole on myelin integrity and cognitive function in schizophrenia.
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients [Phase 2]
A Phase 2 clinical trial evaluating cannabidiol for acutely ill schizophrenia patients was terminated.
-
FDA approval · 2024-12-20FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Fluphenazine Decanoate submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: Validation and Impact of Cardiorespiratory Fitness in Severe Mental Illness - the Heart in Mind Project
The Heart in Mind Project is validating how cardiorespiratory fitness relates to health outcomes in people with severe mental illness, inclu…